Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL298106 | 0.87 | RAB9A (0.31) | MAPTALDH1A1HSD17B10POLBRAB9A | |
| SCHEMBL27855099 | 0.83 | HPGD (0.34) | HPGDALDH1A1TP53HSD17B10 | |
| SCHEMBL297985 | 0.81 | MAPT (0.35) | HPGDMAPTALDH1A1TP53HSD17B10 | |
| SCHEMBL298661 | 0.80 | KMT2A (0.37) | MAPTALDH1A1KDM4EPOLBRAB9A | |
| SCHEMBL660685 | 0.79 | ALDH1A1 (0.40) | HPGDMAPTALDH1A1TP53KDM4E | |
| SCHEMBL661076 | 0.77 | ALDH1A1 (0.33) | MAPTALDH1A1KDM4EMAPK1HTT | |
| SCHEMBL287148 | 0.76 | ALDH1A1 (0.33) | HPGDMAPTALDH1A1HSD17B10KDM4E | |
| SCHEMBL661852 | 0.76 | CTNNB1 (0.34) | HPGDMAPTALDH1A1HSD17B10KDM4E | |
| SCHEMBL27854984 | 0.74 | MAPT (0.34) | MAPTALDH1A1KDM4ERAB9ALMNA | |
| SCHEMBL297726 | 0.73 | MAPT (0.38) | MAPTALDH1A1TP53KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | claimed |
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | DUTT CHAITANYA (IN) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046317-A1 | NOVEL HETEROCYCLIC COMPOUNDS | AGER, REN, AGT | HPGD 202/4885MAPT 61/4885ALDH1A1 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.